Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
PSVT is a common arrhythmia form, influencing people of random ages. The market elements are affected by the frequency of PSVT and its likely effect on the personal satisfaction, inciting the requirement for compelling symptomatic and cooperative arrangements.
Symptomatic devices like electrocardiography (ECG) and electrophysiology studies are necessary to recognizing and affirming PSVT. The market solution developments in these analytic advancements, improving the exactness and effectiveness of diagnosing PSVT episodes.
Continuous checking gadgets, including Holter monitors and event recorders, assume a urgent part in discovery of irregular PSVT episodes. These devices add to a far-reaching understanding of the arrhythmia's sample and help in treatment direction.
Drug choices are a vital part of the PSVT market. Antiarrhythmic medications, beta-blockers, and calcium channel blockers are commonly recommended to oversee PSVT episodes and prevent their recurrence, meaning to reestablish typical heart musicality.
Interventional cardiology techniques, especially catheter removal, are huge in the PSVT market. Catheter removal targets and dispenses with the strange electrical pathways causing PSVT, offering a possible fix or long-haul side effect help for specific patients.
Patient training is vital in overseeing PSVT. Lifestyle alterations, stress management, and evasion of triggers add to the general consideration technique. The market elements incorporate drives advancing patient commitment and self-management for further developed results.
Implantable gadgets, like pacemakers and implantable cardioverter-defibrillators (ICDs), might be considered for people with repetitive or high-risk PSVT. These gadgets screen heart disposition and give restorative intercessions while required, upgrading the market's treatment choices.
The joining of telehealth arrangements is turning out to be progressively important in the PSVT market. Telehealth empowers distant interviews, working with convenient conversations among patients and healthcare suppliers, particularly during episodes or for medicine changes.
Cooperative endeavors among healthcare experts, scientists, and drug organizations drive headways in PSVT treatment. Clinical preliminaries investigate new restorative choices, refine existing agreements, and add to the continuous development of the market.
Paroxysmal Supraventricular Tachycardia Market Highlights:
Paroxysmal Supraventricular Tachycardia (PSVT) Market Scenario
Paroxysmal Supraventricular Tachycardia Market Size was valued at USD 0.28 Billion in 2023. The Paroxysmal Supraventricular Tachycardia industry is projected to grow from USD 0.30 Billion in 2024 to USD 0.52 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.30% during the forecast period (2024 - 2032). Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate that is caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heart beating. People suffering from this disorder experience sudden and unexpected occurrence of rapid heart rate that start and stop without warning. A normal heart beats between 60 to 100 beats per minute, but the heart rate of a person suffering from paroxysmal supraventricular tachycardia during an episode may exceed 150–200 beats per minute.
The prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) is unknown but is projected to be around several cases per thousand persons. But, a recent study conducted by Milestone Pharmaceuticals suggested that about 1.7 million patients in the U.S. were suffering from paroxysmal supraventricular tachycardia since the last five years.
The most common types of arrhythmias include atrial fibrillation, atrial flutter, sick sinus syndrome, sinus tachycardia, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and premature ventricular contractions. Moreover, some arrhythmias may lead to more serious medical problems such as sudden stroke or cardiac arrest.
Intended Audience
- Paroxysmal Supraventricular Tachycardia Drug Manufacturers and Suppliers
- Paroxysmal Supraventricular Tachycardia Treatment Providers
- Imaging Device Manufacturers
- Hospitals and Clinics
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
- Market Research and Consulting Service Providers
- Potential Investors
Figure 1: Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, by Region
Paroxysmal Supraventricular Tachycardia (PSVT) Market Segmentation
The Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), Paroxysmal Atrial Tachycardia (PAT), and Wolff-Parkinson-White Syndrome (WPW).
On the basis of diagnosis, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, cardiac catheterization, coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others. Lab tests are further classified into blood test, urine test, and others.
On the basis of treatment, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, pacemaker, and cardioversion. Medication can be segmented into calcium channel blockers, beta blockers, antiarrhythmic medication, and others. Calcium channel blockers are further divided into diltiazem, verapamil, and others. The antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.
On the basis of end-user, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Paroxysmal Supraventricular Tachycardia (PSVT) Market Regional Analysis
The Paroxysmal Supraventricular Tachycardia (PSVT) market consists of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of stroke, raising awareness among people, and increasing healthcare expenditure. Coronary artery diseases, heart valve disorders, and heart failures are some of the common causes of heart diseases occurring in adults in North America. Thus, the increasing occurrences of heart failure support the growth of paroxysmal supraventricular tachycardia in this region.
Asia Pacific is estimated to be the most lucrative market for PSVT due to the increasing occurrence of multiple heart disorders in Asia Pacific such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.
The growing prevalence of coronary heart diseases along with the increasing medical tourism that requires surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of heart disorders are similarly supporting the growth of paroxysmal supraventricular tachycardia market.
Paroxysmal Supraventricular Tachycardia (PSVT) Market Key Players
Some of the key players in the Paroxysmal Supraventricular Tachycardia (PSVT) market are:
- GlaxoSmithKline PLC (U.K.)
- Novartis AG (Switzerland)
- Pfizer, Inc. (U.S.)
- AstraZeneca PLC (U.K.)
- Teva pharmaceutical industries (Israel)
- Sanofi SA (France)
- Medtronic, Inc. (U.S.)
- Glenmark Pharmaceuticals (U.S.)
- St. Jude Medical, Inc. (U.S.)
- BIOTRONIK SE & Co. KG (U.S.)
- GE Healthcare (U.S.)
- Boston Scientific Corporation (U.S.)
- Abbott Laboratories Inc. (U.S.)
- (Alcon) Novartis (U.S.)
- Siemens AG (Germany)
- Koninklijke Philips N.V. (U.S.)
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
